CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Major Shareholder Sells $325,000.00 in Stock

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) major shareholder Bioventures Opportunities G. Yk sold 3,250,000 shares of the business’s stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $0.10, for a total value of $325,000.00. Following the sale, the insider now directly owns 22,620,783 shares of the company’s stock, valued at $2,262,078.30. This represents a 12.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

CERo Therapeutics Stock Performance

CERO traded down $0.02 during midday trading on Thursday, reaching $0.19. 11,922,732 shares of the company were exchanged, compared to its average volume of 15,181,584. The company’s fifty day moving average price is $0.10 and its 200 day moving average price is $0.36. CERo Therapeutics Holdings, Inc. has a one year low of $0.06 and a one year high of $12.80.

CERo Therapeutics (NASDAQ:CERO) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.33) EPS for the quarter.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.